Saturday, January 18, 2020
Mundipharma today announced a partnership with Samsung Bioepis to commercialize the first biosimilar candidates from Samsung Bioepis in Taiwan and Hong Kong.
The partnership includes biosimilar candidates from Samsung Bioepis in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab) and SB8 (bevacizumab).
The partnership makes Mundipharma the exclusive commercialization partner, while Samsung Bioepis remains the marketing authorization holder (MAH), who is responsible for the clinical development, legal registration and production of the biosimilars.
" This partnership combines the proven biosimilar development platform of Samsung Bioepis with the commercial insight and market insight of Mundipharma and the ability to improve patients' access to proven treatments," said Raman Singh, CEO of Mundipharma. " This partnership will help meet the needs of patients for immunology and oncology treatments in two key areas in Asia," he added.
This announcement is officially valid in the original source language. Translations are only intended as reading aids and must be compared with the text in the source language, which is the only one valid.
